Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dose Level 1 Clear all
Completed Not applicable Interventional Results available

Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection

NCT02241187
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
PEGPH20, Cetuximab, DW & DCE-MRI, blood draws
Drug · Device · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Sep 8, 2026, 8:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women

NCT01721993
View directory record Official record
Conditions
Healthy Postmenopausal Women
Interventions
T121, Zoledronic acid
Drug
Lead sponsor
Thar Pharmaceuticals, Inc
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Sep 8, 2026, 8:05 AM EDT
Completed Phase 2 Interventional Results available

Pharmacological Ascorbate for Lung Cancer

NCT02420314
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Paclitaxel, Carboplatin, Ascorbic Acid
Drug
Lead sponsor
Joseph J. Cullen, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 8, 2026, 8:05 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

NS-050/NCNP-03 in Boys With DMD (Meteor50)

NCT06053814
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
NS-050/NCNP-03, Placebo
Drug
Lead sponsor
NS Pharma, Inc.
Industry
Eligibility
4 Years to 15 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 8, 2026, 8:05 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Transdermal Nicotine on Response Inhibition to Emotional Cues in Schizophrenia

NCT03838484
View directory record Official record
Conditions
Schizophrenia, Impulsive Behavior
Interventions
Nicotine Patch, 7 Mg/24 Hr, Placebo patch
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 8, 2026, 8:05 AM EDT
Active, not recruiting Phase 2 Interventional

The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients

NCT03809533
View directory record Official record
Conditions
Kidney Transplantation, Hepatitis C
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Amit D Tevar, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 8, 2026, 8:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Comparison of Delivery Routes of Flu Vaccine in Adults

NCT00170547
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
1,597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
10
States / cities
Stanford, California • Torrance, California • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Sep 8, 2026, 8:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function

NCT04209049
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0174-0833
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 8, 2026, 8:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Powdered Tart Cherries on Recovery From Repeated Sprints

NCT06122038
View directory record Official record
Conditions
Inflammation, Oxidative Stress, Soreness, Muscle, Muscle Damage
Interventions
Tart Cherry Extract Powder, Placebo
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 8, 2026, 8:05 AM EDT
Terminated Phase 1 Interventional

Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies

NCT01165658
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Small Cell Lung Cancer, Carcinoid, Thymic Cancer, Lung Cancer
Interventions
Proton Therapy
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Sep 8, 2026, 8:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

NCT06345755
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407, Placebo, Midazolam
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 8, 2026, 8:05 AM EDT
Terminated Phase 2 Interventional Results available

5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia

NCT00413478
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Leukemia
Interventions
5-Azacytidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Sep 8, 2026, 8:05 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00972478
View directory record Official record
Conditions
Ann Arbor Stage II Non-Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Prednisone, Rituximab, Vincristine Sulfate, Vorinostat
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
190
States / cities
Mobile, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 132 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 8, 2026, 8:05 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)

NCT06181136
View directory record Official record
Conditions
Mucopolysaccharidosis Type IIIA
Interventions
DNL126
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
0 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Oakland, California • Iowa City, Iowa • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 8, 2026, 8:05 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)

NCT03168464
View directory record Official record
Conditions
Non Small Cell Lung Cancer Metastatic
Interventions
Ipilimumab, Nivolumab, Radiation therapy
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
19 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Sep 8, 2026, 8:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Single and Multiple Ascending Dose Study of MT-701

NCT07396909
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MT-701
Drug
Lead sponsor
Mirador Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 8, 2026, 8:05 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Metabolic Causes of Thrombosis in Type 2 Diabetes Mellitus

NCT00829699
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
euinsulinemic euglycemic glucose clamp, euinsulinemic hyperglycemic glucose clamp, Hyperinsulinemic euglycemic glucose clamp, Hyperinsulinemic hyperglycemic glucose clamp
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Sep 8, 2026, 8:05 AM EDT
Completed Phase 1 Interventional Results available

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

NCT03388632
View directory record Official record
Conditions
Metastatic Solid Tumors, Treatment-Refractory Cancers
Interventions
rhIL-15, Ipilimumab, Nivolumab, Tumor biopsies, EKG, ECHO, CT Scan
Drug · Procedure · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 8, 2026, 8:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

NCT04393298
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
ginisortamab, trifluridine/tipiracil, mFOLFOX6
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Charleston, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 8, 2026, 8:05 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

NCT01369498
View directory record Official record
Conditions
Myelofibrosis
Interventions
Simtuzumab, Ruxolitinib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
7
States / cities
Scottsdale, Arizona • Stanford, California • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Sep 8, 2026, 8:05 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

NCT04104893
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
Pembrolizumab
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
13
States / cities
San Francisco, California • West Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 8, 2026, 8:05 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients

NCT05616793
View directory record Official record
Conditions
LCA5
Interventions
AAV8.hLCA5
Biological
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
4 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 8, 2026, 8:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Clinical Study to Assess the Safety of a New Influenza Vaccine

NCT01104493
View directory record Official record
Conditions
Healthy
Interventions
Monovalent Frozen FluMist®, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
South Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 17, 2011 · Synced Sep 8, 2026, 8:05 AM EDT
Completed Phase 2 Interventional Results available

Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate

NCT01426438
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Niacin, Aspirin, Fenofibrate
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 8, 2026, 8:05 AM EDT